Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +40.59%
#2 Bitway Bitway +24.85%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.60%
#4 Starpower Starpower +20.76%
#5 aelf aelf +18.07%
#6 Pons Pons +15.54%
#7 Decred Decred +13.45%
#8 Venom Venom +12.68%
#9 DAPPOS DAPPOS +11.63%
#10 Ribbita by Virtuals Ribbita by Virtuals +11.17%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Tvardi Therapeutics, Inc. Tvardi Therapeutics, Inc.

Tvardi Therapeutics, Inc.

TVRD
Kedudukan dalam Saham #30251
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages... Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Harga Saham
$1.88
Disegerakkan terakhir: 2026-08-18
Modal Pasaran
$17.59M
Perubahan (1 hari)
0.81%
Perubahan (1 tahun)
-92.40%
Negara
US
Perdagangan Tvardi Therapeutics, Inc. (TVRD)

Kategori

Healthcare
Pendapatan untuk Tvardi Therapeutics, Inc. (TVRD)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Tvardi Therapeutics, Inc., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Tvardi Therapeutics, Inc. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE